Aug 12, 2020
Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing
Jun 10, 2020
F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
Jun 04, 2020
Athlete's Foot - Market Insights, Epidemiology and Forecast to 2030
May 19, 2020
Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
May 19, 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
May 12, 2020
Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020
Mar 11, 2020
Antimicrobial Textile Market, 2020-2025: Analysis, Drivers, Restraints & Forecast - ResearchAndMarkets.com
Mar 09, 2020
F2G Receives US FDA Orphan Drug Designation for Olorofim
Jan 22, 2020
Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015
Jan 08, 2020
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
Jan 08, 2020
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Dec 12, 2019
Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015
Nov 12, 2019
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
Oct 24, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Oct 21, 2019
Moberg Pharma and DongKoo Sign Agreement for MOB-015 in the Republic of Korea
Oct 15, 2019
United States Onychomycosis Market Size, Trends & Forecasts Report 2019-2023
Oct 02, 2019
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Sep 24, 2019
Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
Sep 16, 2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
Sep 09, 2019
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications